VOLU SOL INC
10QSB/A, EX-27, 2000-08-02
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: VOLU SOL INC, 10QSB/A, EX-10, 2000-08-02
Next: EXE TECHNOLOGIES INC, S-1/A, 2000-08-02



<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>               SEP-30-2000
<PERIOD-START>                  JAN-01-2000
<PERIOD-END>                    MAR-31-2000
<CASH>                                       1,123,846
<SECURITIES>                                         0
<RECEIVABLES>                                   86,932
<ALLOWANCES>                                   (2,188)
<INVENTORY>                                     49,446
<CURRENT-ASSETS>                             1,258,036
<PP&E>                                         399,650
<DEPRECIATION>                               (332,161)
<TOTAL-ASSETS>                               1,329,647
<CURRENT-LIABILITIES>                          222,538
<BONDS>                                              0
                                0
                                  3,577,916
<COMMON>                                         1,222
<OTHER-SE>                                 (2,249,491)
<TOTAL-LIABILITY-AND-EQUITY>                 1,329,647
<SALES>                                        256,734
<TOTAL-REVENUES>                               256,734
<CGS>                                          165,144
<TOTAL-COSTS>                                  165,144
<OTHER-EXPENSES>                             1,249,301
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (1,155,750)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,155,750)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                              (117,087)
<CHANGES>                                            0
<NET-INCOME>                               (1,272,837)
<EPS-BASIC>                                     (1.48)
<EPS-DILUTED>                                   (1.48)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission